| 01/11/2022 09:30 |
Presentation: Better health for people, Brighter future for the world |
| 01/11/2022 09:30 |
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference |
| 01/05/2022 15:00 |
Takeda Provides Update on Status of Acquisition of Own Shares |
| 12/16/2021 13:00 |
Takeda Submits New Drug Application for Novavax' COVID-19 Vaccine Candidate in Japan |
| 12/01/2021 15:00 |
Takeda Provides Update on Status of Acquisition of Own Shares |
| 11/30/2021 17:00 |
The 145th (interim period) Business Report |
| 11/05/2021 16:00 |
Quarterly Securities Report(The second quarter of 145th Business Term) for The Six-month Period and Three-month Quarter Ended September 30, 2021 |
| 11/01/2021 19:30 |
Takeda Applied for Selection of Prime Market, Filed CG Report with TSE in Line with Revised CG Code and Published CG related Documents on its website |
| 11/01/2021 13:15 |
Corporate Governance Report 2021/11/01 |
| 10/28/2021 15:00 |
Takeda Announces Acquisition of Own Shares |
| 10/28/2021 15:00 |
Summary of Financial Statements for the Six-month Period Ended September 30, 2021 (IFRS,Consolidated) |
| 10/08/2021 10:30 |
Takeda Sets Terms and Conditions for its 10-Year Denominated Unsecured Senior Bond |
| 10/06/2021 08:30 |
Takeda Provides Update on TAK-994 Clinical Program |
| 10/01/2021 12:00 |
Statement regarding Moderna COVID-19 Vaccine Recall Investigation Report - October 2021 |
| 09/07/2021 10:35 |
Takeda to Manufacture and Provide 150 Million Doses of Novavax' COVID-19 Vaccine Candidate to the Government of Japan |
| 09/07/2021 10:00 |
Takeda's Response to the New Incident Announced by the Japanese MHLW |
| 09/01/2021 21:00 |
Joint Statement from Moderna and Takeda on the Investigation of Suspended Lots of Moderna's COVID-19 Vaccine in Japan |
| 08/28/2021 17:00 |
Moderna and Takeda's Response to the Incidents Announced by the Japanese Ministry of Health, Labour and Welfare (MHLW) associated with the Announced S |
| 08/26/2021 17:00 |
Notice of Suspension of Use of Specific Lots of Moderna's COVID-19 Vaccine in Japan (COVID-19 Vaccine Moderna Intramuscular Injection) |
| 08/07/2021 08:00 |
(Revised) Takeda's Executive Compensation Overview |
| 08/06/2021 16:00 |
Quarterly Securities Report (The first quarter of 145th Business Term) for The Three-month Period Ended June 30, 2021 |
| 08/06/2021 15:00 |
Revision of the Summary of Financial Statements for the Three-month Period Ended June 30, 2021 (IFRS,Consolidated) |
| 08/02/2021 08:30 |
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie |
| 07/30/2021 15:00 |
Summary of Financial Statements for the Three-month Period Ended June 30, 2021 (IFRS,Consolidated) |
| 07/20/2021 17:30 |
Takeda Expands Moderna's COVID-19 Vaccine Supply in Japan in Partnership with the Japanese Government |
| 07/19/2021 15:45 |
Corporate Governance Report 2021/07/19 |
| 07/08/2021 15:30 |
Notice Concerning Issuance of New Shares under the Long-Term Incentive Plan for Company Group Employees Overseas |
| 07/02/2021 12:00 |
Annual Securities Report From April 1, 2020 to March 31, 2021 (The 144th Fiscal Year) |
| 06/30/2021 00:30 |
2021 ANNUAL INTEGRATED REPORT |
| 06/29/2021 16:30 |
Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan for the Issuance of New Shares |
| 06/22/2021 08:00 |
(Correction) Takeda's Executive Compensation Overview |
| 06/22/2021 08:00 |
Partial Correction to the Notice of Convocation of the 145th Ordinary General Meeting of Shareholders |
| 05/29/2021 08:00 |
Takeda's Executive Compensation Overview |
| 05/29/2021 08:00 |
Message from Christophe Weber, President & CEO |
| 05/29/2021 08:00 |
Items Disclosed via the Internet Concerning the Notice of Convocation |
| 05/29/2021 08:00 |
Notice of Convocation of the 145th Ordinary General Meeting of Shareholders |
| 05/21/2021 13:45 |
Takeda Announces Approval of Moderna's COVID-19 Vaccine in Japan |
| 05/11/2021 17:30 |
Takeda Proposes Partial Amendment to the Articles of Incorporation |
| 05/11/2021 17:30 |
Notice Concerning Issuance of New Shares through Third-Party Allotment associated with Continuation of Stock Grant System for Company Group Management |
| 05/11/2021 17:30 |
Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Group Management in Japan in Fiscal Year 2021 |
| 05/11/2021 15:00 |
Difference between Forecast and Actual Results for the Fiscal Year Ended March 2021 |
| 05/11/2021 15:00 |
Financial Statements for the Fiscal Year Ended March 31, 2021 (IFRS, Consolidated) |
| 04/06/2021 17:00 |
Wave 1 Pipeline Market Opportunity Conference Call Part 2 (on April 6, 2021) Presentation |
| 04/02/2021 21:00 |
Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine |
| 04/01/2021 09:00 |
Takeda Completes Sale of Four Diabetes Productsin Japan to Teijin Pharma Limited |
| 03/31/2021 16:00 |
Takeda Announces Candidates for New Directors |
| 03/31/2021 15:00 |
Takeda Completes Sale of its Japan Consumer Health Care Business Unit to Blackstone |
| 03/11/2021 19:30 |
Growth and Emerging Markets Strategic Update Call (on March 11, 2021) Presentation |
| 03/05/2021 15:00 |
Takeda Submits New Drug Application to Import and Distribute Moderna's COVID-19 Vaccine Candidate in Japan |
| 02/26/2021 16:00 |
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited |
| 02/24/2021 15:00 |
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax'and Moderna's COVID-19 Vaccine Candidates in Japan |
| 02/12/2021 16:00 |
Quarterly Securities Report (The third quarter of 144th Business Term) for The Nine-month Period and Three-month Quarter Ended December 31, 2020 |
| 02/04/2021 15:00 |
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) |
| 02/04/2021 15:00 |
Summary of Financial Statements for the Nine-month Period Ended December 31, 2020 (IFRS, Consolidated) |
